Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | USP2 | O75604 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | PARL | Q9H300 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | METAP1 | P53582 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10128106 | 0.81 | TOP2A (0.42) | TOP2ACYP1A2USP2CYP2C19ALDH1A1 | |
| SCHEMBL21935843 | 0.78 | TOP2A (0.44) | TOP2ACYP1A2USP2CYP2C19ALDH1A1 | |
| SCHEMBL3360410 | 0.76 | TOP2A (0.38) | TOP2A | |
| SCHEMBL21935842 | 0.74 | TOP2A (0.42) | TOP2ACYP1A2USP2CYP2C19ALDH1A1 | |
| SCHEMBL1433450 | 0.72 | TOP2A (0.36) | TOP2ACYP1A2ALDH1A1 | |
| SCHEMBL21898783 | 0.71 | TOP2A (0.39) | TOP2ACYP1A2USP2CYP2C19ALDH1A1 | |
| SCHEMBL19706805 | 0.69 | TOP2A (0.39) | TOP2ACYP1A2USP2CYP2C19ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3328806 | 0.69 | TOP2A (0.41) | TOP2ACYP1A2ALDH1A1CLK4CYP2C9 | |
| SCHEMBL21372391 | 0.68 | TOP2A (0.33) | TOP2A | |
| SCHEMBL21372395 | 0.67 | TOP2A (0.32) | TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300476-B1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2014-01-08 | — | — | EP | disclosed |
| US-8097628-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-01-17 | — | — | US | disclosed |
| EP-2300476-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20090306089-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| WO-2009141398-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306089-A1 | COMPOUNDS | SDHA, NQO1, SDHB | TOP2A 838/4885CYP1A2 80/4885USP2 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.